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X-ray structure of antistasin at 1.9 Å resolution and
its modelled complex with blood coagulation
factor Xa
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that is a major component of blood clots. Coagulation Herman A.Schreuder2, Anita Arkema,
factor Xa plays an important role in this cascade of events, Bijtske de Boer, Kor H.Kalk, Wim G.J.Hol3,
since it converts the zymogen prothrombin into thrombin, Peter D.J.Grootenhuis4,
the enzyme that catalyses the formation of ﬁbrin from John W.M.Mulders4, Rein Dijkema4,
ﬁbrinogen. Furthermore, factor Xa cleaves and hence Henri J.M.Theunissen4 and
activates other components of the coagulation cascade, Bauke W.Dijkstra5
including factors V, VII, VIII and IX (see Padmanabhan
et al., 1993 for references). Laboratory of Biophysical Chemistry and BIOSON Research Institute,
Department of Chemistry, University of Groningen, Nijenborgh 4, Inhibitors of factor Xa might be used as drugs for the
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condition in which blood coagulation occurs in an uncon-
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antistasin, a potent reversible inhibitor of factor Xa, 2Present address: Hoechst Aktiengesellschaft,
displays antithrombotic activity in various in vivo models 65926 Frankfurt am Main, Germany
3Present address: Department of Biological Structure and of venous and arterial thrombosis (Nutt et al., 1991;
Howard Hughes Medical Institute, University of Washington, Vlasuk et al., 1991; Dunwiddie et al., 1992a; Mellott Box 357742, Seattle, WA 98195, USA
et al., 1992; Hauptmann and Kaiser, 1993). Apart from
5Corresponding author its anticoagulant activity, antistasin is able to suppress
metastasis, possibly also via inhibition of factor Xa
The three-dimensional structure of antistasin, a potent (Tuszinsky et al., 1987). It is this antimetastatic property inhibitor of blood coagulation factor Xa, from the from which antistasin obtained its name. Originally, Mexican leech Haementeria ofﬁcinalis was determined antistasin was isolated from the salivary glands of the at 1.9 Å resolution by X-ray crystallography. The
Mexican leech, Haementeria ofﬁcinalis, but since then, it structure reveals a novel protein fold composed of two
has been cloned into eukaryotic expression vectors and homologous domains, each resembling the structure
overexpressed (Han et al., 1989; Nutt et al., 1991; of hirustasin, a related 55-residue protease inhibitor.
Theunissen et al., 1994). The puriﬁed protein has an However, hirustasin has a different overall shape than
inhibition constant for factor Xa of approximately the individual antistasin domains, it contains four
5310210 M and displays competitive, slow-tight binding rather than two b-strands, and does not inhibit factor
inhibition characteristics (Dunwiddie et al., 1989). Anti- Xa. The two antistasin domains can be subdivided into
stasin is rather selective for factor Xa: it hardly inhibits two similarly sized subdomains with different relative
other serine proteases such as thrombin, chymotrypsin, orientations. Consequently, the domain shapes are
pancreatic elastase and leukocyte elastase (Dunwiddie different, the N-terminal domain being wedge-shaped
et al., 1989). andtheC-terminaldomainﬂat.Dockingstudiessuggest
Antistasin is a small, disulﬁde cross-linked protein of that differences in domain shape enable the N-terminal,
but not C-terminal, domain of antistasin to bind and 119 amino acid residues (Mr 5 15 kDa). Figure 1 shows
inhibit factor Xa, even though both have a very similar acomparisonofitsaminoacidsequencewiththesequences
reactive site. Furthermore, a putative exosite binding oftherelatedproteinase inhibitorsghilantenandhirustasin.
region could be deﬁned in the N-terminal domain of Ghilanten is a factor Xa inhibitor isolated from the salivary
antistasin, comprising residues 15–17, which is likely glands of the Amazonian leech, Haementeria ghiliani
to interact with a cluster of positively charged residues (Condra et al., 1989; Blankenship et al., 1990; Brankamp
on the factor Xa surface (Arg222/Lys223/Lys224). This et al., 1990); hirustasin was identiﬁed in the salivary
exosite binding region explains the speciﬁcity and glands of the European medicinal leech, Hirudo medicin-
inhibitory potency of antistasin towards factor Xa. In alis (So ¨llner et al., 1994). The latter protein is an inhibitor
the C-terminal domain of antistasin, these exosite of tissue kallikrein, trypsin and chymotrypsin, but it does
interactions are prevented due to the different overall not inhibit factor Xa.
shape of this domain. Alignment of the 20 cysteines present in antistasin
Keywords: antistasin/crystal structure/factor Xa/protease reveals a 2-fold internal repeat, suggesting that the protein inhibitor/thrombosis has evolved via gene duplication (Nutt et al., 1988). The
tworepeats areverysimilar:the N-terminaldomain(amino
acid residues 1–55) and the C-terminal domain (amino Introduction acid residues 56–119) display ~40% identity and ~56%
homology in their amino acid sequences (Dunwiddie et al., Blood coagulation proceeds through the sequential activ-
ation of a number of plasma serine proteases, ultimately 1989). Between cysteines 82 and 88 in the C-terminal
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Fig. 1. Amino acid sequences of antistasin-type inhibitors. The sequences of antistasin (Nutt et al., 1988; Han et al., 1989; Theunissen et al., 1994),
ghilanten (Blankenship et al., 1990) and hirustasin (So ¨llner et al., 1994) are aligned. For antistasin, the sequence of the recombinant protein, of
which the structure is presently discussed, is given in the upper line. Underneath, amino acid substitutions with respect to this sequence are indicated
for ghilanten and antistasin isoforms. Cysteines are highlighted by asterisks; a dash indicates a gap in the protein sequence. The position of the
reactive site arginine is marked by an arrow.
domain, there is one insertion of a single amino acid Residues 9–11, 94 and some side chains developed tem-
perature factors of ~50 Å2 and higher during reﬁnement. residue compared with the corresponding cysteines in the
N-terminal domain. Furthermore, the C-terminal domain These residues are disordered in the crystal structure.
Several other amino acids, for example Phe50, Glu56, has a nine-residue extension with four positively charged
amino acids. Ser65, Met71 and Arg75, may adopt two different con-
formations of which only the most prominent has been Mutation studies have shown that only the N-terminal
domain of antistasin is necessary for the inhibition of modelled. The overall geometry of both antistasin struc-
tures is good, as can be judged from the r.m.s. deviations factor Xa; the C-terminal domain does not contribute to
its inhibitory activity (O’Neill Palladino et al., 1991; from ideal geometry given in Table I and from the absence
of outliers in the Ramachandran plot (not shown). The Theunissen et al., 1994). The reactive site of antistasin is
formed by Arg34 (the P1-residue) and Val35 (the P19- electron density map (Figure 2) is in good agreement with
the published sequence and, in addition, establishes the residue) in the N-terminal domain (Dunwiddie et al.,
1989). Factor Xa slowly cleaves the peptide bond between so far unknown disulﬁde bond connectivities.
these residues. The C-terminal residues equivalent to
Arg34 and Val35 are Arg89 and Lys90, respectively. A Overall structure
Figure 3 shows the 1.9 Å 3D-structure of antistasin as a Lys90®Val substitution, however, did not restore the
inhibitory activity towards factor Xa (Hofmann et al., simpliﬁed ribbon model. As could be expected on the
basis of the internal sequence homology, antistasin consists 1992; Theunissen et al., 1994), indicating that there are
other factors causing the inactivity of the C-terminal of two structurally similar domains, the N-terminal domain
(residues 1–55) and the C-terminal domain (residues 56– domain.
To investigate the mechanism of action of antistasin 119), in agreement with the prediction of Nutt et al.
(1988). The domains are spatially distant with no inter- and the atomic details of its interaction with factor
Xa, we initiated the crystal structure determination of domain backbone–backbone interactions and only few
side chain–main chain and side chain–side chain inter- antistasin. A preliminary crystallographic analysis has
been published previously (Schreuder et al., 1993). Here, actions. They can further be subdivided into four similarly
sized subdomains, two in each domain. The subdomains we report the 3D-structure of antistasin at 1.9 Å resolution
and suggest a model of the antistasin–factor Xa complex, are linked by two hinge regions, consisting of Val31 and
Arg32 in the N-terminal domain, and Asp85, Ile86 and based on the antistasin and factor Xa crystal structures.
Our structural results indicate that antistasin uses reactive Asn87 in the C-terminal domain. Since the hinge is more
open in the C-terminal domain, this domain adopts a ﬂat site as well as exosite interactions to bind to factor Xa.
shape, whereas the N-terminal domain is wedge-shaped
(see Figure 4). The difference in linker angle is caused Results by the insertion of Asp85 and by the special f,y angles
of Gly30 (91° and 160°). In the C-terminal domain, the Electron density map and quality of the model
Table I summarizes the ﬁnal results of the crystallographic residue corresponding to Gly30 is an isoleucine. However,
apart from the differences in the hinge regions, the reﬁnement of antistasin. Two antistasin structures have
been determined, one at room temperature (2.3 Å resolu- individual subdomains superimpose very well, with r.m.s.
differences of Ca atoms being only 0.60 Å for residues tion) and one at 100 K to a resolution of 1.9 Å. A
superposition of the two structures revealed root mean 33–55 and 88–110 and 0.77 Å for residues 13–30 and
67–84. square (r.m.s.) differences for Cas of 0.28 Å, a value
close to the coordinate error of the two structures as
determined from a Luzzati plot (not shown). The crystallo- Folding pattern of the domains in antistasin
Antistasin appears to exhibit mainly random coil structure graphic R-factors are 19.4% and 21.7%, respectively, for
the 2.3 Å and 1.9 Å structures. In both cases, the ﬁnal (see Figure 3). Although two short antiparallel b-strands
can be identiﬁed in each of the two domains on the basis model consists of amino acid residues 7–110. For the six
N-terminal and the nine C-terminal residues, the density of f,y angles (involving residues 41–43 and 49–53 in the
N-terminal domain and residues 96–98 and 104–108 is too weak to deﬁne their positions with conﬁdence.
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Table I. Reﬁnement statistics
Temperature (K) 293 100
Resolution range (Å) 5.0–2.3 5.0–1.9
Reﬂections used [Fo . 0s(Fo)] 5711 9103
Final R-factor (%)a 19.4 21.7
Average real-space correlation coefﬁcient (%)
sA-weighted (2Fo – Fc) map 0.91 0.91
sA-weighted (2Fo – Fc) OMIT map 0.86 0.87
Residues included 7–110 7–110
Number of non-H atoms
Protein 790 790
Non-protein 62 89
R.m.s. deviations from ideality for bond lengths (Å) 0.012 0.015
R.m.s. deviations from ideality for bond angles (°) 2.53 1.49
Secondary structure analysis according to PROCHECK (Laskowski et al., 1993)
Residues in most favoured regions (%) 87.6 87.6
Residues in additional allowed regions (%) 12.4 12.4
Residues in generously allowed regions (%) 0.0 0.0
Residues in disallowed regions (%) 0.0 0.0
Average B-factors (Å2)
Protein atoms 29.5 25.5
Solvent 40.3 30.3
Protein Data Bank code 1SKZ
aR-factor 5 (S||Fo|–|Fc||/S|Fo|).
Fig. 2. Representative part of the sA-weighted (Read, 1986) (2Fo–Fc) OMIT map (Bhat, 1988; Vellieux and Dijkstra, 1997), centred at Arg34 and
contoured at 1s, showing the hydrophobic interaction network which stabilizes the reactive site loop of antistasin. Cysteines 33 and 51 and cysteines
37 and 53 are connected by disulﬁde bonds, respectively. The density for the side chain of Arg32 is somewhat weak. This residue is positioned close
to a crystallographic 2-fold axis and has rather high B-values.
in the C-terminal domain, respectively), they lack the A remarkable feature of the antistasin structure is the
absence of a proper core, which is also reﬂected by the appropriate hydrogen bonding interactions and thus do
not form real sheets. Also in the rest of the structure, fact that only 1144 Å2 of the total accessible surface of
antistasin (7394 Å2) are buried. Instead, disulﬁde bridges main chain hydrogen bonding interactions are very limited.
Instead, side chain contacts dominate the antistasin struc- seem to stabilize the fold. Antistasin contains 20 cysteine
residues, 10 in each domain, all of which are involved in ture. There are no a-helices present in antistasin, only
one single a-helical turn. This turn involves residues 8– disulﬁde bridges. They are usually ﬂanked by hydrophobic
residues forming four small hydrophobic clusters, one in 11 and is positioned in a region with very high temperature
factors. In addition, several reverse turns exist. each subdomain, at topologically identical positions. In
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Fig. 3. Stereo view of the overall structure of antistasin from H.ofﬁcinalis [produced with Molscript (Kraulis, 1991)]. The P1 and P19 residues Arg34
and Val35, as well as Glu15 of the putative exosite binding region of antistasin are indicated.
Fig. 4. Stereo view showing the superposition of the N- and C-terminal domains of antistasin, based on the Ca coordinates of the second
subdomains, respectively [using the program O (Jones et al., 1991); ﬁgure produced with Molscript (Kraulis, 1991)]. The N-terminal domain (black)
adopts a wedge shape, while the C-terminal domain (grey) is relatively ﬂat.
the N-terminal domain, disulﬁde bonds are observed chain is considerably less exposed. The reactive site loop
is connected to the rest of the protein by two disulﬁde between residues 8–19, 13–26, 28–48, 33–51 and 37–53
and in the C-terminal domain between residues 62–73, bonds involving Cys33 and Cys37 and is further stabilized
by a network of hydrophobic interactions between these 67–80, 82–103, 88–106 and 92–108 (see Figure 5). Hence,
all the disulﬁde bridges are within the individual domains, two disulﬁdes and the Val31, Phe41 and Val35 side
chains (see Figure 2). As a consequence of the various and two of them (involving Cys28/48 and Cys82/103)
cross-bridge the subdomains. interactions, the temperature factors in the reactive site
region are rather low, with values of ~15 Å2 for most
residues. For Cys33 and Arg34, temperature factors are The reactive site region
The reactive site of antistasin is formed by Arg34 (the somewhathigher,withvaluesclosetotheaveragetempera-
ture factor of antistasin, which is 26 Å2. Temperature P1-residue) and Val35 (the P19-residue) in the N-terminal
domain (Dunwiddie et al., 1989). Arg34 is positioned at factors are highest for Arg32 (up to 50 Å2 for side chain
atoms). Thus, although the reactive site loop is highly the tip of an exposed loop at the protein surface (see Figure
3). Its side chain has adopted an extended conformation. In exposed, it has a well-deﬁned conformation. Only the side
chains of Arg32 and Arg34 are somewhat more ﬂexible the crystal, this residue is involved in contacts with a
symmetry-related molecule. Val35 is pointing into the and may adapt their conformation to ﬁt optimally into the
active site of the target protease. opposite direction. Compared with Arg34, the Val35 side
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Fig. 5. Schematic representation of the antistasin fold. The orientation of antistasin is similar to the one chosen in Figure 3. Disulﬁde connectivities
and the linker residues connecting the two subdomains within each domain are indicated. The scissile bond is marked by an arrow. b-strands involve
amino acid residues 41–43 and 49–53 in the N-terminal domain and residues 96–98 and 104–108 in the C-terminal domain, respectively.
In the C-terminal domain of antistasin, the correspond- analyse possible binding modes of antistasin with its target
ing part of the reactive site (residues 87–92) also forms protease. Antistasin was docked with its binding loop into
an exposed loop, positioned at the opposite end of the the active site cleft of human factor Xa (Padmanabhan
protein molecule. Its overall structure is very similar to et al., 1993; Brandstetter et al., 1996) as described in
the equivalent N-terminal region, as is reﬂected by the Materials and methods (see Figure 6A). Docking was
low r.m.s. differences in Ca positions of 0.43 Å for guided by the structures of the kallikrein A–BPTI (Chen
residues 88–92 compared with residues 33–37. As in the and Bode, 1983) and trypsin–BPTI (Marquart et al., 1983)
N-terminal domain, an arginine residue (Arg89) is at the complexes. Only the side chain of the P3 residue Arg32
position corresponding to P1, and also the network of had to be manually reoriented to optimize its ﬁt in the
hydrophobic interactions has a counterpart in the active site. The resulting energy-minimized structure of
C-terminal domain, however, with Val31, Val35 and Phe41 antistasin exhibits r.m.s. differences for Cas of 0.40 Å
being replaced by Ile86, the aliphatic part of the Lys90 compared with the X-ray structure. For residues 32–39,
side chain and Leu96, respectively. r.m.s. differences are even smaller (0.35 Å), indicating
Although the reactive site and its C-terminal counterpart that only minor changes were required for complex form-
appear very similar at ﬁrst sight, some differences exist. ation with factor Xa. Two major sites of antistasin were
Most obvious is the substitution of Val35 by Lys90. Other found to interact with factor Xa, consisting of residues
differences include a different side chain conformation of 15–17 and 32–39, respectively. Additional contact zones
Arg89 compared with Arg34, the increased temperature may include the backbone carbonyl oxygen atoms of
factors for residues 90–97 compared with residues 35–42, antistasin residues 8, 9 and 51, which are likely to interact
and the differences in f,y angles, especially for residues with the side-chain amino groups of Lys148 and Lys96
N-terminalofresidue88and33,respectively(seeTableII). of factor Xa, respectively. In the following, the two major
interaction sites will be discussed in detail.
Modelling of the factor Xa–antistasin complex
The reactive site region (residues 32–39). As in the As we have not obtained crystals of a complex of antistasin
with factor Xa, we performed docking studies in order to uncomplexed structure of antistasin, the side chain of the
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Table II. Main chain conformational angles f,y of reactive site loops
P3 P2 P1 P19 P29 P39
Antistasin domain 1 Arg32 Cys33 Arg34 Val35 His36 Cys37
f/y (°) –93/39 –156/178 –129/29 –59/132 –71/112 –113/110
Antistasin domain 2 Asn87 Cys88 Arg89 Lys90 Thr91 Cys92
f/y (°) 33/70 –125/125 –119/27 –77/146 –105/131 –136/138
Canonical values (from Bode and Huber, 140°,f,–120° –100°,f,–60° –120°,f,–95° –100°,f,–60° –140°,f,–99° –140°,f,–99°
1992)
140°,y,170° 139°,y,180° 9°,y,50° 139°,y,180° 70°,y,120° 70°,y,120°
(except BPTI)
Fig. 6. Representative views of the modelled complex of antistasin and factor Xa. (A) Stereo view of the Ca trace [produced with Molscript
(Kraulis, 1991) and Raster3D (Merritt and Murphy, 1994)]. Antistasin residues Glu15, Arg32 (P3), Arg34 (P1) and Val35 (P19) are highlighted.
(B) Reactive site area. Possible interactions of antistasin residues Arg32 and Arg34 with factor Xa are indicated. Ser195 of the factor Xa catalytic
triad is perfectly positioned for nucleophilic attack by the protease.
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P1 residue Arg34 adopts an extended conformation in the In view of the fact that only the N-terminal domain of
antistasin can inhibit factor Xa, even though the C-terminal modelled complex with factor Xa. It forms a salt bridge
with twin–twin geometry to Asp189 at the bottom of the domain is highly homologous, it seemed very interesting
also to perform docking studies of factor Xa with the S1 speciﬁcity pocket of factor Xa (see Figure 6B). The
interaction is similar to that of Arg439 from a symmetry- C-terminal domain of antistasin. As a result, the inability
of the C-terminal domain to inhibit factor Xa seems related molecule in the native factor Xa crystal structure
(Padmanabhan et al., 1993). In addition to the ionic mainly to be caused by sites other than the region
corresponding to the antistasin reactive site. Although at interactions, the Arg34 side chain is likely to be involved in
hydrogen bonding interactions with the backbone carbonyl ﬁrst sight, clashes of this part of antistasin with factor Xa
seem inevitable, at second sight, they appear resolvable. oxygen atoms of factor Xa residues 190, 216 and 218.
The main chain carbonyl oxygen of Arg34 points into the For instance Arg89, which corresponds to the P1 residue,
can easily reorient its side chain such that it adopts the oxyanion hole of factor Xa and probably forms hydrogen
bonds with Ser195 N and Gly193 N. In the modelled same conformation as Arg34. And even Lys90, a residue
much longer than the equivalent Val35 (P19), can probably complex, the scissile bond linking Arg34 and Val35 is
sandwiched between the side chains of factor Xa residues be accommodated into the corresponding factor Xa pocket.
Much more serious are the clashes observed between Ser195 and Gln192, respectively, with the Arg34 carbonyl
carbon being positioned only 2.9 Å from the serine Og of antistasin residues Asn87 and, to a lesser extent, Asp85
with residues Trp215 and Phe174 of factor Xa, respect- the factor Xa catalytic triad (His57, Asp102 and Ser195).
This inhibitor atom thus seems perfectly positioned for ively. These two residues are positioned in the linker
peptide which connects the two subdomains of the anti- nucleophilic attack by the protease.
The majority of serine proteases of the trypsin/chymo- stasin C-terminal domain. Another important difference
to the modelled complex of factor Xa with the N-terminal trypsin family form an antiparallel b-sheet with their
substrates or inhibitors which involves residues 214–216 domain of antistasin is the absence of the exosite inter-
actions. Even though the residue corresponding to Glu15 from the protease. However, in the modelled complex
with antistasin, these residues seem not to contribute to is also conserved in the C-terminal domain of antistasin,
it is positioned ~10 Å away from the corresponding hydrogen bonding interactions. This ﬁnding is in agree-
ment with the results from Brandstetter et al. (1996) who position in the N-terminal domain, due to the different
arrangement of subdomains in the two antistasin domains. determined the crystal structure of factor Xa with the
synthetic inhibitor DX-9065a. The lack of b-sheet inter- In its position in the C-terminal domain, Glu69 cannot
interact with factor Xa. Hence, although the C-terminal actions is compensated for by two other major interactions
between antistasin and factor Xa. One has already been equivalent of the reactive site loop does not differ that
much from its N-terminal counterpart, proper interaction described and involves the P1 residue Arg34. The second
important interaction between antistasin and factor Xa with factor Xa is prevented by steric hindrance of the
linker peptide and the absence of the exosite interactions. concerns the P3 residue Arg32. In the modelled complex,
the Arg32 guanidinium group binds to the cation hole of
factor Xa, which is formed by the carbonyl oxygens of Discussion
Lys96 and Glu97 as well as the Glu97 carboxylate
(Brandstetter et al., 1996) (see Figure 6B). The aliphatic The antistasin structure and comparison with
other protease inhibitors part of the Arg32 side chain partly occupies the aryl
binding site (S4) of factor Xa. The P4 residue Val31 is Antistasin consists of two structurally similar domains
both of which are mainly stabilized by ﬁve intra-domain positioned far away from this binding site and seems not
to interact with factor Xa. Thus, two residues, Arg32 and disulﬁde bridges at topologically identical positions. Other
protease inhibitors have been described, which are Arg34, are likely to be particularly important for the
interaction of antistasin with factor Xa, with most of the similarly rich in disulﬁde bridges, and also lack extensive
secondary structural elements, such as squash seed interaction potential of the side chains of these residues
satisﬁed. inhibitor-I (Bode et al., 1989) or mucous proteinase
inhibitor (Gru ¨tter et al., 1988). However, a more detailed The exosite binding region (residues 15–17).A n
unprecedented feature of the antistasin structure is the comparison of the various structures, including a DALI
search (Holm and Sander, 1993), revealed that only the region comprising residues 15–17. In our model, the Glu15
side chain, which interacts with Arg25 from a symmetry- protein hirustasin exhibits signiﬁcant structural homology
with antistasin. The structure of hirustasin was published, related molecule in the crystal structure, is reoriented
towards a cluster of three positively charged residues, in complex with kallikrein (Mittl et al., 1997), when
ﬁnalizing this manuscript. Hirustasin is a related 55- Arg222, Lys223 and Lys224, on the surface of factor Xa.
We will refer to this contact area as the ‘exosite’. Evidence residue protease inhibitor which shares 29% sequence
identity with the N-terminal domain of antistasin and 38% exists that this putative exosite may not be unique for
factor Xa, but may also be present in other proteases, with its C-terminal domain. It has a fold similar to the
individual domains of antistasin and also has the same since many factor Xa-related proteases like thrombin and
trypsin also have positively charged amino acid residues disulﬁde connectivity. As could be expected from the
degree of sequence homology, hirustasin resembles the at corresponding positions (Jackson and Nemerson, 1980).
In addition to the charge–charge interactions, antistasin structure of the ﬂat C-terminal domain rather than that
of the wedge-shaped N-terminal domain of antistasin. and factor Xa may form contacts via two hydrogen bonds
involving the main chain carbonyl of Ser17 and the side However, hirustasin comprises two additional short, anti-
parallel b-strands in the ﬁrst subdomain and also exhibits chain of Arg222, respectively.
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a different relative orientation of the two subdomains that the disulﬁdes might have an additional function. By
covalently attaching the reactive site region to Cys51 and compared with antistasin.
On the basis of a sequence alignment, the individual Cys53, two closely linked residues, the disulﬁde bonds
could prevent the two peptide chains from moving too far domains of antistasin were expected also to share a similar
fold with decorsin and hirudin (Krezel et al., 1994). apart after cleavage of the scissile bond, thus facilitating
re-formation of the peptide bond. In this way, factor Xa Although the sequence alignment has ultimately proven
incorrect (Mittl et al., 1997), cysteine residues 8, 13, 19 would be inhibited by antistasin in a reversible manner,
as has been observed by Dunwiddie et al. (1992b). and 26 of the ﬁrst subdomain of the antistasin N-terminal
domain do superimpose with the corresponding cysteines
17, 22, 27 and 38 of decorsin. In fact, r.m.s. differences Interaction of antistasin with factor Xa
Why is antistasin such a potent (sub-nanomolar) factor for the cysteine Ca positions are only 0.27 Å and also
the disulﬁde connectivity is the same. For the C-terminal Xa inhibitor? The results of structure determination and
docking studies suggest that the interactions between domain of antistasin, the superposition is somewhat worse
(r.m.s.d. 5 1.1 Å). However, the spacing of the cysteine factor Xa and antistasin involve two sites of factor Xa,
the active site and an exosite. The reactive site loop of residues is different in the two structures and the loops
connecting the cysteine residues do not superimpose. antistasin is suited for binding to the active site binding
pockets of factor Xa, with the strongest interactions most Similar results are found for a superposition with the
corresponding cysteines of hirudin, although here the likely involving the S1 pocket and the cation hole of
factor Xa and the P1 and P3 residues of antistasin, superposition of the connecting loops is somewhat better.
Thus, although the overall structures of decorsin and respectively (Figure 6B). In addition, the region around
antistasin residue Glu15 seems to be ideally positioned to hirudin differ from the antistasin and hirustasin structures,
respectively, they do exhibit highly conserved elements. interact with a cluster of positively charged residues on
the factor Xa surface (residues 222–224). A multi-site
binding that includes spatially remote sites is thermo- Comparison of the N- and C-terminal domains of
antistasin dynamically favourable because the total loss of entropy
upon complexation ‘has already been paid for’ during the The presence of 2-fold symmetry in the antistasin structure
raises the possibility that this protein is a so-called ﬁrst interaction.
‘multiheaded’ inhibitor, similar to members of the
Bowman–Birk, Kunitz and Kazal inhibitor families Implications for other factor Xa inhibitors
In the antistasin-like serine protease inhibitor hirustasin, (reviewed by Laskowski and Kato, 1980). These proteins
accommodate more than one reactive site. In contrast, the the spacing of the ten cysteines is nearly identical to
that in antistasin (see Figure 1) and also the disulﬁde inhibitory activity of antistasin seems to be limited to its
N-terminal domain, with only the peptide bond between connectivity is consistent (Mittl et al., 1997). Hirustasin
inhibitstissuekallikrein,trypsin,chymotrypsinandneutro- Arg34 and Val35 being cleaved by factor Xa (Dunwiddie
et al., 1989; O’Neill Palladino et al., 1991; Theunissen phil cathepsin G, but it does not inhibit factor Xa. Why
is this so? Of the eight amino acid residues in the P5–P39 et al., 1994). The absence of inhibitory activity of the
C-terminal domain seems to be caused mainly by the region of hirustasin, ﬁve residues are identical to those in
antistasin and ghilanten isoforms (Nutt et al., 1988; overall shape of this domain. While in the N-terminal
domain Arg32 (P3) is involved in an important contact Blankenship et al., 1990). Residues Arg32, Val35 and
His36 of antistasin are replaced by histidine, isoleucine with factor Xa, the corresponding residue in the C-terminal
domain, Asn87 and, to a somewhat lesser extent also and arginine, respectively, in hirustasin. In our docking
studies, Arg32 (P3) has been found to be involved in one Asp85,exhibitseriousclasheswithfactorXa.Furthermore,
the different positioning of the two subdomains prevents of the most important interactions with factor Xa. It binds
to the cation hole of factor Xa which is formed by the the interactions of the C-terminal domain of antistasin
with the putative exosite of factor Xa. Thus, structural carbonyl oxygens of Lys96 and Glu97 as well as the
Glu97 carboxylate. A histidine residue is much smaller reasons clearly indicate why only the N-terminal and not
the C-terminal domain of antistasin exhibits inhibitory than an arginine and would not reach into the cation hole
unless factor Xa would undergo a structural change. activity against factor Xa. However, from our results it
cannot be excluded that an as yet unidentiﬁed protease is Furthermore, the putative exosite interaction of Glu15 in
the ﬁrst domain of antistasin with the Arg222/Lys223/ inhibited by the antistasin C-terminal domain.
Lys224 cluster in factor Xa is not possible in hirustasin,
since the corresponding amino acid residue in hirustasin Reactive site
Thereactivesite[Arg34(P1)andVal35(P19)]ispositioned is an alanine (So ¨llner et al., 1994) (Figure 1). Antistasin
and ghilanten isoforms, which all inhibit factor Xa, all in an exposed loop which is connected to the rest of the
protein by two disulﬁdebonds involving Cys33 and Cys37. have a glutamate residue at this position.
In the crystal structure of the hirustasin–kallikrein Removal of one of the disulﬁde bonds by mutating Cys33
to glycine had no dramatic effect on the inhibitory activity complex (Mittl et al., 1997), the most important inter-
actions between inhibitor and protease are found to involve of antistasin (Theunissen et al., 1994), suggesting that
Cys33 is not essential for activity. In the crystal structure, the P1 and the P4 residues, rather than P1 and P3 as for
antistasin. Even though the P4 residue is a valine in the two disulﬁdes contribute to a tight hydrophobic inter-
action network involving also Val31, Phe41 and Val35. hirustasin as well as in antistasin, this residue has a
different function in the two proteins. While in antistasin The disulﬁdes thus clearly contribute to the stability of
the reactive site loop. However, it is tempting to speculate Val31 is involved in a tight hydrophobic interaction
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Table III. Data collection and phasing statistics
Data set Resolution Measured Unique Rmerge (%) Completeness No. of Rderiv RCullis Phasing
(Å) reﬂections reﬂections (%) sites power
Native 1 2.8 10608 3295 6.0 93
Native 2 2.3 51863 6384 6.8 100
Native 3a 1.9 100326 10300 8.0 95
K2PtCl4-1 2.8 11710 3363 7.2 95 2 0.21 0.71 1.33
K2PtCl4-2 2.8 9197 3133 6.0 90 2 0.23 0.65 1.46
PIP 2.8 12026 3430 4.2 97 3 0.32 0.62 0.99
UO2-acetate 3.2 8896 1672 7.2 67 4 0.13 0.68 0.96
Rmerge 5 Sh Si |I(h)i–,I(h).|/Sh,I(h)., where I(h)i are the intensity measurements for a reﬂection and ,I(h). is the mean intensity for this
reﬂection.
Rderiv 5 Sh |FPH–FP|/Sh|FP|, where FPH and FP are the structure factor amplitudes of the derivative and native crystals, respectively.
RCullis 5 Sh||FPH 6 FP|–FH(calc)|/Sh|FPH–FP|, where FPH and FP are deﬁned as above, and FH(calc) is the calculated heavy atom structure factor
amplitude summed over centric reﬂections only.
Phasing power 5, F H . /E, the r.m.s. heavy atom structure factor amplitude divided by the lack of closure error.
PIP 5 di-imul-iodobis(ethylenediamine)-di-platinum(II)-nitrate.
aThe data set native 3 was obtained by scaling a 90% complete 1.9 Å data set collected at DESY (Rsym 5 3.8%) to a 2.5 Å data set collected in
house, also at cryogenic temperature.
EMBL outstation at DESY. Both beam lines were equipped with network, which stabilizes the reactive site loop, the corres-
MAR image plate detectors. Data were processed using the BIOMOL ponding Val27 of hirustasin adopts an exposed position
(Groningen, NL) and CCP4 (Daresbury, UK) suites as well as XDS
at the protein surface suited for a strong interaction with (Kabsch, 1988a,b, 1993). Details of data collection are given in Table III.
kallikrein. Hence, although the structures of antistasin and
hirustasin are similar, the existing differences account for Phasing
The heavy-atom sites of the platinum derivatives could be located by highly speciﬁc interactions with the target proteases.
inspection of the Harker sections of difference Patterson maps and by
performing vector search calculations. The power of the derivatives was Conclusion limited because of common sites. The binding sites of the uranyl
The X-ray structure of antistasin reveals a novel folding derivative were found from difference Fouriers. The occupancy of these
sites was unfortunately very low. After reﬁnement of the heavy-atom motif of a protease inhibitor which consists of two
parameters using PHARE (Bricogne, 1976), the overall ﬁgure of merit domains, each resembling the structure of hirustasin.
to 3.5 Å resolution was 0.56. Table III summarizes the phasing statistics. Antistasin predominantly consists of random coil structure,
stabilized by ten disulﬁde bonds. The modelled factor Xa– Model building and reﬁnement
antistasin complex suggests at least two interaction sites The quality of the initial MIR map calculated at 3.5 Å resolution was
of the inhibitor with the target protease. These two sites poor, but some polypeptide chains could be built into it. Several cycles
of constrained and restrained reﬁnement with phase combination with are presumably essential for the inhibitor’s speciﬁcity and
the MIR phases and model building using FRODO (Jones, 1985) binding afﬁnity. At present we are investigating the relative
improved both the model and the map considerably and the chain could importance of these interaction sites by mutational analysis be traced, except for some N- and C-terminal residues. Crystallographic
inspired by the modelled complex of factor Xa and reﬁnement was done using RESTRAIN (Driessen et al., 1989) and
X-PLOR (Bru ¨nger et al., 1987). Reﬁnement of the room temperature antistasin. In addition, the modelled complex is used for
model of antistasin at 2.3 Å resolution resulted in an R-factor of 19.2% the design of novel low-molecular weight inhibitors.
and a free R-factor of 26.4%. The last reﬁnement cycle was repeated
for all reﬂections including the test set, giving a ﬁnal R-factor of 19.4%.
The ﬁnal model of the antistasin structure at room temperature consists Materials and methods
of amino acid residues 7–110 and includes 62 water molecules. Sub-
sequently, this structure without the water molecules was taken as the Antistasin preparation, crystallization and data collection
starting model for reﬁnement of the cryo structure of antistasin. After Recombinant antistasin, produced in Chinese hamster ovary cells, was
rigid-body reﬁnement, the R-factor was 36.8%. Seven rounds of reﬁne- prepared and crystallized with ammonium sulfate and sodium chloride
ment using X-PLOR and subsequent manual rebuilding of the model as precipitants as described before (Schreuder et al., 1993; Theunissen
using O (Jones et al., 1991), resulted in a ﬁnal R-factor of 21.5% and a et al., 1994). Antistasin crystallizes in space group I422 with cell
free R-factor of 27.4%. The corresponding R-factors at 2.3 Å resolution dimensions a 5 b 5 78.3 Å and c 5 88.5 Å. The crystals contain one
are 19.5% and 26.2%, respectively. The last reﬁnement cycle was protein molecule per asymmetric unit. Heavy-atom derivatives were
repeated with all the data including the test set and resulted in a structure prepared by soaking crystals in 0.2 mM K2PtCl4 (1 day), 5 mM di-imul-
with good stereochemistry and an R-factor of 21.7%. The ﬁnal model iodobis(ethylenediamine)-di-platinum(II)-nitrate (2 days) or 10 mM
at cryogenic temperature includes amino acids 7–110, 88 water molecules uranyl acetate (5 days). For cryo experiments, antistasin crystals were
and one chloride ion. Reﬁnement statistics are summarized in Table I. pre-equilibrated for 2 days against a reservoir containing 30% ammonium
Coordinates and structure factors have been submitted to the Protein sulfate, 2.2 M sodium chloride, 100 mM sodium citrate buffer, pH 6.0
Data Bank under accession code 1SKZ. and 20% glycerol. Crystals were then transferred to this solution, in
which they were stable for at least 2 weeks, before actually performing
the cryo experiments. Upon ﬂash-freezing, the cell parameters of the Modelling the interaction of antistasin with factor Xa
All molecular modelling studies were carried out with Quanta/CHARMm antistasin crystals shrank to a 5 b 5 76.5 Å and c 5 86.6 Å.
Native and derivative data were collected on a FAST area detector 96 (MSI, San Diego). The all atom force ﬁeld was used for factor Xa
(4469 atoms) and antistasin (1536 atoms). The N- and C-termini were mounted on a rotating anode X-ray generator operated at 40 kV and
80 mA. In addition, two higher-resolution native data sets were collected charged by applying default patches. Coordinates of human factor Xa
in complex with the inhibitor DX-9065a were kindly provided to us by at synchrotron radiation sources, one at room temperature (native 2) and
one at cryogenic temperature (native 3). The 2.3 Å room temperature Dr Richard Engh (Max-Planck-Institut fu ¨r Biochemie, Martinsried).
Docking of the antistasin binding loop onto the active site cleft of factor data set was collected on beam line 9.7 at the SRS, Daresbury Laboratory,
while the 1.9 Å cryo data set was collected on beam line BW7A at the Xa was guided by the structures of the kallikrein A–BPTI [PDB entry
5159R.Lapatto et al.
2KAI (Chen and Bode, 1983)] and trypsin–BPTI [PDB entry 2PTC Dunwiddie,C.T., Vlasuk,G.P. and Nutt,E.M. (1992b) The hydrolysis and
(Marquart et al., 1983)] complexes, assuming that the relative position resynthesis of a single reactive site peptide bond in recombinant
and orientation of the binding loops and the active sites in all these antistasin by coagulation factor Xa. Arch. Biochem. Biophys., 294,
complexes are similar. Only the side chain of the P3 residue Arg32 had 647–653.
to be manually reoriented to optimize its ﬁt in the active site. In the Grootenhuis,P.D.J. and van Galen,P.J.M. (1995) Correlation of binding
antistasin crystal structure, any other than the observed conformation of afﬁnities with non-bonded interaction energies of thrombin-inhibitor
Arg32 would lead to clashes with a symmetry-related molecule. Energy complexes. Acta Crystallogr., D51, 560–566.
minimizations were carried out using the Newton–Raphson algorithm Gru ¨tter,M.G., Fendrich,G., Huber,R. and Bode,W. (1988) The 2.5 Å
until the r.m.s. value of the energy gradient was ,0.2 kcal/mol·Å. X-ray crystal structure of the acid-stable proteinase inhibitor from
Initially, only the residues in the contact zone were energy-minimized, human mucous secretions analysed in its complex with bovine
while the rest of the system was kept ﬁxed. In a second step, the whole a-chymotrypsin. EMBO J., 7, 345–351.
system was energy-minimized without applying constraints. During Han,J.H. et al. (1989) Cloning and expression of cDNA encoding
energy minimization, the electrostatics were scaled down by using a antistasin, a leech-derived protein having anti-coagulant and anti-
distance-dependent dielectric function of e 5 2R (Grootenhuis and van metastatic properties. Gene, 75, 47–57.
Galen, 1995). Switching and shifting functions were turned on for Hauptmann,J. and Kaiser,B. (1993) Anticoagulant and antithrombotic
distances up to 11 and 14 Å for the van der Waals and electrostatic action of the Factor Xa inhibitor antistasin (ATS). Thromb. Res., 71,
interactions, respectively. 169–174.
Hofmann,K.J., Nutt,E.M. and Dunwiddie,C.T. (1992) Site-directed
mutagenesis of the leech-derived Factor Xa inhibitor antistasin.
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